Górecki Lukáš

For Czech version click here

Postdoctoral fellow
LukasGorecki@seznam.cz
ORCID: 0000-0002-4791-6556
Researcher ID: N-9017-2019
ResearchGate: https://www.researchgate.net/profile/Lukas_Gorecki

Dr. Lukas Gorecki graduated from Charles University, Faculty of Pharmacy in Hradec Kralove. He continued as postgraduate student at the Department of Toxicology and Military pharmacy, Faculty of Military Health Sciences, University of Defense, where he was dealing with design and synthesis of cholinesterases modulators. Throughout his Ph.D. studies various fields of these enzymes were inspected. His main topic was introduction of novel acetylcholinesterase reactivators as antidotes against organophosphorous compounds, such as Nerve Agents, the most toxic chemical weapons of mass destruction. This was also the subject of his internship at UCSD, one of the leading research facilities in this field. Currently, he is employed as postdoc at Biomedical Research Center, University Hospital Hradec Kralove, where he continues with the search for novel antidotes against Nerve Agents. Besides, he is now fulltime involved as young researcher in the development of novel chemotherapeutics for individualized anticancer approach. This is laid on the “tailored medicine” principle, to provide the most suitable therapeutics for a certain patient. At present, dr. Gorecki is dealing with the three different approaches. 1) development of novel selective ATR inhibitors as sensitizers of standard radio‑ or chemotherapy; 2) development of novel chemosensitizers for temozolomide against glioblastoma multiforme; 3) development of novel FLT3 inhibitors, including its resistant form, for the treatment of acute myeloid leukemia.

Education

Research focus

Medicinal chemistry – project management, design, synthesis, structure‑activity relationships, and basic biochemical evaluation in novel cholinesterases modulators and chemotherapeutics for individualized anticancer approach.

Professional training

International experiences

Further extracurricular activities

Awards

Publication acitivity

Author or co‑author 24 scientific publications with IF

H-Index: 10 (WoS)

Citations without autocitations: 295

(dated 03/2022)

Five selected publications

(1) Gorecki, L.; Gerlits, O.; Kong, X.; Cheng, X.; Blumenthal, D. K.; Taylor, P.; Ballatore, C.; Kovalevsky, A.; Radić, Z. Rational Design, Synthesis and Evaluation of Uncharged, “Smart” Bis-Oxime Antidotes of Organophosphate-Inhibited Human Acetylcholinesterase. J. Biol. Chem. 2020, jbc.RA119.012400. https://doi.org/10.1074/jbc.RA119.012400. IF₂₀₂₀ = 5.157 (first author)

(2) Gorecki, L.; Andrs, M.; Rezacova, M.; Korabecny, J. Discovery of ATR Kinase Inhibitor Berzosertib (VX-970, M6620): Clinical Candidate for Cancer Therapy. Pharmacol. Ther. 2020, 107518. https://doi.org/10.1016/j.pharmthera.2020.107518. IF₂₀₂₀ = 12.31 (first author)

(3) Gorecki, L.; Andrs, M.; Korabecny, J. Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer. Cancers 2021, 13 (4), 795. https://doi.org/10.3390/cancers13040795. IF₂₀₂₀ = 6.639 (first author)

(4) Gorecki, L.; Hepnarova, V.; Karasova, J. Z.; Hrabinova, M.; Courageux, C.; Dias, J.; Kucera, T.; Kobrlova, T.; Muckova, L.; Prchal, L.; Malinak, D.; Jun, D.; Musilek, K.; Worek, F.; Nachon, F.; Soukup, O.; Korabecny, J. Development of Versatile and Potent Monoquaternary Reactivators of Acetylcholinesterase. Arch. Toxicol. 2021, 95 (3), 985–1001. https://doi.org/10.1007/s00204-021-02981-w. IF₂₀₂₀ = 5.153 (first author)

(5) Gorecki, L.; Misiachna, A.; Damborsky, J.; Dolezal, R.; Korabecny, J.; Cejkova, L.; Hakenova, K.; Chvojkova, M.; Karasova, J. Z.; Prchal, L.; Novak, M.; Kolcheva, M.; Kortus, S.; Vales, K.; Horak, M.; Soukup, O. Structure-Activity Relationships of Dually-Acting Acetylcholinesterase Inhibitors Derived from Tacrine on N-Methyl-d-Aspartate Receptors. Eur. J. Med. Chem. 2021, 219, 113434. https://doi.org/10.1016/j.ejmech.2021.113434. IF₂₀₂₀ = 6.514 (first author)